Antengene

Pipeline

  1. Envafolimab
    Target/Mechanism

    PD-L1

    Rights

    Worldwide

    Indication

    MSI-H/dMMR advanced cancer (mono, 2L+)

    Partner
    MORE
    MSI-H/dMMR advanced cancer (mono, 2L+)
    Advanced BTC (combo with chemo vs. chemo, 1L)
    NSCLC (Adjuvant/Neo-adjuvant therapy, 1L)
    G/GEJ advanced cancer (combo with chemo, 1L)
    TMB-H advanced cancer (mono, 2L+)
    EC (mono and combo with lenvatinib, 2L+)
    HCC, CRC, NSCLC (combo with BD0801)
    Microsatellite stable CRC (combo with cetuximab+/- Fruquintinib, standard treatment failure)
    dMMR advanced solid tumors (mono, 2L+)
    Preclinical
    IND
    Phase I
    Phase II
    Phase Ⅲ
    NDA Filing
    Marketing
  2. 3D189
  3. 3D229
  4. 3D1001
  5. 3D1002
  6. 3D185
  7. 3D011
  8. 3D197
  9. 3D057
  10. 3D124
  11. 3D060
  12. 3D062